News

Under Voyager’s Collaboration Agreement with Sanofi Genzyme, Sanofi Genzyme had an exclusive option for ex-U.S. development and commercial rights to VY-AADC. Based on Voyager’s understanding that because this

MCL represents 3% to 10% of all non-Hodgkin lymphoma cases in the US, as per the National Cancer Institute at the National Institutes of Health. Calquence functions by

This approval follows a FDA Priority Review and is based on data from EINSTEIN CHOICE, the only clinical study to find that a Factor Xa inhibitor, specifically XARELTO,

The license agreement permits Lannett to manufacture and market in the U.S. its generic thalidomide product as of August 1, 2019 or earlier under certain circumstances.  As mandated

The transaction is expected to help Novartis with near-term product launches along with the addition of a new technology platform with potential applications in various oncology early development

The company has revealed positive top-line results from three pivotal phase 3 clinical trials assessing risankizumab compared to ustekinumab and adalimumab to treat patients with moderate to severe

Results showed an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years with oral Gilenya compared to treatment with interferon

The company did not reveal the exact reason behind the withdrawal of the Marketing Authorisation Application (MAA) of the Keytruda combination. However, the company's move is due to an

“About 80 percent of women with ovarian cancer are diagnosed in the advanced stages when the disease is difficult to treat and options are limited,” said Sandra Horning,